Your SlideShare is downloading. ×
ENDEAVOR IV trial - Summary & Results
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

ENDEAVOR IV trial - Summary & Results

257
views

Published on

http://www.theheart.org/web_slides/1135907.do …

http://www.theheart.org/web_slides/1135907.do

A randomized, single-blind study comparing Zotarolimus and Paclitaxel-Eluting Stents (ENDEAVOR IV) in more than 1500 patients with CAD

Published in: Health & Medicine, Technology

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
257
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. ENDEAVOR IV (Randomized Comparisonof Zotarolimus- and Paclitaxel-ElutingStents in Patients With CAD)
  • 2. ENDEAVOR IV (Randomized Comparison of Zotarolimus-and Paclitaxel-Eluting Stents in Patients With CAD)M Leon (Columbia University, New York, NY)Transcatheter Cardiovascular Therapeutics 2007 Meeting• A randomized, single-blind study comparing the Endeavor and Taxus stents in more than 1500 patients• Primary outcome: Target vessel failure: a composite of cardiac death, MI, and target vessel revascularization at nine months
  • 3. ENDEAVOR IV: ResultsENDEAVOR IV: ENDEAVOR IV:Nine- and 12-month results Eight-month angiographic follow-upEnd point Endeavor (%) Taxus (%) p End point Endeavor Taxus p9-mo TVF 6.6 7.2 <0.001* % diameter 26 16 <0.001 stenosis, in-stent12-mo TVF 7.7 9.4 0.267 % diameter 32 26 0.004 stenosis, in-segment9-mo TVR 5.4 4.9 0.728 Late loss, in-stent 0.67 0.42 <0.001 (mm)12-mo TVR 6.3 6.7 0.753 Late loss, 0.36 0.23 0.023 in-segment (mm)• Endeavor stent noninferior to Taxus • In-segment late lumen loss greaterin terms of primary end point for Endeavor stentTVF = target vessel failure; TVR = target vessel revascularization*p for noninferiority
  • 4. ENDEAVOR IV: Commentary*"We think this is an important trial because its the basis for approval of the next[drug-eluting stent] in the United States. I wouldnt necessarily use the worldblockbuster. " - Dr Marty Leon"My concern is whether the failure of Endeavor to meet the noninferioritysecondary end point of in-segment late loss may become even more evident in ahigher-risk patient cohort. . . . But that still remains to be demonstrated." - Dr Patrick Serruys*All comments from Endeavor IV results get mixed reviews: Interventionalists prove a tougher crowdthan FDA panel (http://www.theheart.org/article/820229.do)
  • 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.

×